139 related articles for article (PubMed ID: 15888191)
1. Extensive plaque psoriasis successfully treated with adalimumab (Humira).
Sladden MJ; Mortimer NJ; Hutchinson PE
Br J Dermatol; 2005 May; 152(5):1091-2. PubMed ID: 15888191
[No Abstract] [Full Text] [Related]
2. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
3. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
4. Marked improvement in nail psoriasis during treatment with adalimumab.
Irla N; Yawalkar N
Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab.
Hirche D; Rubbert A; Lunau L; Krieg T; Eming SA
Br J Dermatol; 2005 May; 152(5):1062-4. PubMed ID: 15888173
[No Abstract] [Full Text] [Related]
7. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
[TBL] [Abstract][Full Text] [Related]
8. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade).
Mang R; Ruzicka T; Stege H
Br J Dermatol; 2004 Feb; 150(2):379-80. PubMed ID: 14996123
[No Abstract] [Full Text] [Related]
10. Switching biologics for psoriasis.
Ormerod AD
Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
[No Abstract] [Full Text] [Related]
11. A scientific debate: key clinical questions in the management of psoriasis.
Stingl G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
[No Abstract] [Full Text] [Related]
12. Potential future therapies for psoriasis.
Papp KA
Semin Cutan Med Surg; 2005 Mar; 24(1):58-63. PubMed ID: 15900800
[No Abstract] [Full Text] [Related]
13. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Ryan C; Kirby B; Collins P; Rogers S
Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
[TBL] [Abstract][Full Text] [Related]
14. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
Moreno-Ramírez D
Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
[No Abstract] [Full Text] [Related]
15. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
16. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
17. Pityriasis rubra pilaris successfully treated with adalimumab.
Schreml S; Zeller V; Babilas P; Karrer S; Landthaler M; Szeimies RM
Clin Exp Dermatol; 2010 Oct; 35(7):792-3. PubMed ID: 20345992
[No Abstract] [Full Text] [Related]
18. Adalimumab (Humira): a brief review for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2004 Dec; 15(6):348-52. PubMed ID: 15764045
[TBL] [Abstract][Full Text] [Related]
19. Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
Woo WA; Waite A; Rustin MH; McBride SR
Br J Dermatol; 2014 Apr; 170(4):989-90. PubMed ID: 24298875
[No Abstract] [Full Text] [Related]
20. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
